A New Innovation in the Prevention of Birth Prior to 37 Weeks Gestation

A New Innovation in the Prevention of Birth Prior to 37 Weeks Gestation

A New Innovation in the Prevention of Birth Prior to 37 Weeks Gestation
RestartResume
Dr. Sibai and Dr. Smith discuss one of the most important issues surrounding obstetrics: the prevention of preterm birth.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    In light of the availability of a subcutaneously administered 17-OHPC, this activity will discuss strategies for providing optimal clinical management to women at risk for PTB, based on the SMFM, ACOG, and ACNM recommendations. In addition, it will provide information surrounding the pharmacokinetic principles underlying the determination of pharmacologic bioavailability and bioequivalence, and the clinical data supporting the bioequivalence of 17-OHPC administered subcutaneously compared to the intramuscular injection. It will also define the impact of this new route of 17-OHPC administration on patient and practitioner parameters.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:

    Amy Mackey, MD
    Vice Chair, Residency Program Director
    Patient Safety Officer
    Department of Obstetrics and Gynaecology
    Abington Hospital-Jefferson Health

    Dr. Mackey receives consulting fees from Clinical Innovations.

    Faculty: 

    Bahaeddine M. Sibai, MD
    Professor of Ob/Gyn
    Director, MFM Fellowship Program
    McGovern Medical School
    The University of Texas Health Science Center at Houston
    Department of Obstetrics, Gynecology, and Reproductive Sciences
    Houston, TX

    Dr. Sibai has nothing to disclose.

    Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP
    Associate Professor
    Director, WHIM Research Program
    McGovern Medical School
    The University of Texas Health Science Center at Houston
    Women’s Health Integrative Medicine Research Program
    Department of Obstetrics, Gynecology, and Reproductive Sciences
    Houston, TX

    Dr. Smith receives consulting fees from Clovis Oncology, Pfizer Oncology, and Shire and has contracted research with Diawa Pharmaceutical.

    Reviewers/Planners/Authors:

    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Incorporate strategies for providing optimal clinical management to women at risk for PTB, based on SMFM, ACOG, and ACNM recommendations.
    • Define the bioavailability and bioequivalence data regarding subcutaneous administration of 17-OHPC compared with intramuscular administration.
    • Describe the impact of subcutaneous dosing of 17-OHPC on patient and practitioner parameters.
  • Target Audience

    This activity is designed to meet the educational needs of maternal fetal medicine specialists, obstetricians and gynecologists, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from AMAG Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Global Women's Health Academy newsletters.
Comprehensive Women's Health Education.

Better education for a better you.

* Required
Optional
Register

Join the Global Women's Health Academy of learners.
Registration is free and easy.

Register Now